Initial Public Offering, Pharmaceutical and Securities

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Initial Public Offering

Pharmaceutical

Securities

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value. Why did life sciences outperform the market?

M&A

M&A Mergers and Acquisitions Pharmaceutical Acquisitions

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A

M&A Mergers and Acquisitions Pharmaceutical Collaboration

Investment Banking Today

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley’s 2022 Life Sciences M&A Year in Review

Stay Connected